Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARX788 in advanced HER2+ solid tumors
NCT03255070Phase 1Completed
- Sponsor
- Ambrx
- Start
- Mar 2018
- Primary completion
- Sep 2023
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 2
01
Overview
Phase 1, open-label trial of anvatabart opadotin in breast cancer, gastric cancer (GC) and solid tumor (2 arms), sponsored by Ambrx. Primary endpoints: Treatment Emergent Adverse Events and Objective Response Rate at 36 months. Started Mar 2018; status: completed.
02
Drugs
anvatabart opadotin
03
Conditions
breast cancergastric cancer (GC)solid tumor
Beyond the preview
Go deeper on NCT03255070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03255070.